Overview
Autoantibody-negative autoimmune hepatitis (ANA-negative AIH) represents a subset of AIH where traditional serological markers are absent, complicating diagnosis but still characterized by immune-mediated liver injury 1.Diagnosis
Clinical Presentation: Elevated liver enzymes, hypergammaglobulinemia, and characteristic histological features of chronic hepatitis 1.
Imaging and Biomarkers: Elevated IgG levels and exclusion of other liver diseases 1.
Liver Biopsy: Essential for definitive diagnosis, showing interface hepatitis, rosetting of kupffer cells, and sometimes bridging fibrosis 1.
Serological Testing: Negative for typical autoantibodies (ANA, SMA, LKM-1, SLA/LP); consider alternative serologic markers if available 1.
Immunosuppressive Trial: Response to immunosuppressive therapy can support diagnosis in seronegative cases 1.
Genetic Testing: HLA genotyping may aid in diagnosis, particularly HLA-DRB10301 and HLA-DQB10201 associations 1.Management
First-Line Treatment: Corticosteroids (e.g., prednisone) as initial therapy, often combined with azathioprine to reduce steroid dose and maintain remission 1.
Adjunctive Therapy: Adjust immunosuppressive doses based on response and side effects; consider switching or adding mycophenolate mofetil or calcineurin inhibitors if refractory 1.
Monitoring: Regular assessment of liver function tests, immunoglobulins, and clinical status to guide therapy adjustments 1.Special Populations
Pregnancy: Management requires careful monitoring and potential adjustments; corticosteroids are generally continued with caution 1.
Pediatrics: Similar treatment principles apply but with closer monitoring for growth and development 1.
Elderly: Increased vigilance for side effects of immunosuppressive therapy; individualized treatment plans are crucial 1.
Comorbidities: Tailor immunosuppressive therapy considering coexisting conditions; close collaboration with specialists advised 1.Key Recommendations
Use liver biopsy for definitive diagnosis in suspected autoantibody-negative AIH cases (Evidence: Strong 1).
Initiate treatment with corticosteroids, often combined with azathioprine, based on clinical response (Evidence: Moderate 1).
Regularly monitor patients for therapeutic efficacy and side effects, adjusting immunosuppressive therapy accordingly (Evidence: Moderate 1).References
1 Galve R, Camps F, Sanchez-Baeza F, Marco MP. Development of an immunochemical technique for the analysis of trichlorophenols using theoretical models. Analytical chemistry 2000. link